← Leaderboards
Jacob Glanville
Centivax Inc
$2,987,953
Attributed
$2,987,953
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $996.8K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$2,987,953 · 1
By mechanism
R44$2,987,953 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Experimental Study”
- Mari Ostendorf · University Of Washington$51,931,230
- Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
- Samuel W Teitelbaum · Arizona State University$13,377,213
- Jason Dickens · Duke University$12,259,409
- Suma Babu · Massachusetts General Hospital$11,004,714
- Sabrina Paganoni · Massachusetts General Hospital$11,004,714
Research focus
Experimental StudyAmericanAdverse EventAnimalsAnimal SourcesAntibodiesAntibody RepertoireAdverse ReactionsBiteCell LineCellsCessation Of LifeClinical TrialsCommercializationCostDangerousnessAntiveninsAnaphylaxisDoseEarly ExperienceEarly OnsetElapidaeEquus CaballusExposure To
Grant awards (3)
Development of World's First Fully Human Broad Spectrum Anti-Snake Venom$996,813
R44 · FY2025 · AI · contact PI
Development of World's First Fully Human Broad Spectrum Anti-Snake Venom$995,570
R44 · FY2024 · AI · contact PI
Development of World's First Fully Human Broad Spectrum Anti-Snake Venom$995,570
R44 · FY2023 · AI · contact PI